| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI technologies in medical imaging help analyze images faster and with high precision, assisting radiologists in detecting diseases such as cancers, fractures, and other abnormalities. This leads to earlier and more accurate diagnoses, which can significantly improve patient treatment and outcomes. |
According to a 2019 article in Nature Medicine, AI is transforming healthcare by enhancing how medical images are analyzed to improve patient outcomes. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI supports radiologists by providing an additional layer of analysis, helping to confirm or identify findings that might be missed. This “second opinion” role improves diagnostic confidence and accuracy, ultimately benefiting patient care. |
A 2019 article in Nature Medicine highlights how AI tools assist radiologists by acting as a second pair of eyes in interpreting medical images. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
This means having the skills to comprehend how AI works, its capabilities, limitations, and how to use it responsibly especially important for healthcare professionals integrating AI into their practice. |
The 2019 Nature Medicine article explains that AI literacy is crucial for effectively adopting AI technologies in medical fields. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
Factors like trust in AI, how well AI fits into existing workflows, understanding the system, and openness to new technology all affect whether healthcare professionals accept AI. But the color or appearance of AI devices doesn’t impact acceptability. |
It doesn't need any source or evidence it's just common sense that color does not affect. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
This means that colleagues, professional networks, and organizational culture can shape whether healthcare workers trust and adopt AI tools in their practice. |
As discussed in the 2019 Nature Medicine article, social factors play a key role in AI acceptance among medical professionals. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
A common perceived threat about AI in healthcare is the fear that it might replace healthcare professionals. Many worry AI could take over jobs or reduce the need for human expertise. This concern affects how some practitioners feel about adopting AI tools. Addressing these fears is important for smoother integration. |
2019 article in Nature Medicine discussing healthcare workers’ views on AI. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
This means creating AI tools that fit well with doctors’ workflows, support their decision-making, and are easy to understand and use. When AI is designed around people’s needs, healthcare professionals are more likely to trust and adopt it. |
2019 Nature Medicine article emphasizing the importance of human-centred design in healthcare AI. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
This means how well the AI system fits into daily work, its usefulness, and how easily it can be incorporated into existing processes. These aspects strongly influence whether healthcare professionals will adopt the technology. |
2019 Nature Medicine article discussing key factors affecting AI acceptance in healthcare settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality plays a big role in whether healthcare professionals accept AI. It affects how they view AI based on whether the technology aligns with their professional values and ethical standards. If AI systems are seen as respecting patient privacy, fairness, and transparency, doctors and nurses are more likely to trust and use them. On the other hand, if AI raises ethical concerns like bias, lack of accountability, or threats to patient confidentiality it can lead to resistance or skepticism. So, ensuring AI tools meet ethical expectations is crucial for gaining acceptance in medical settings. |
This idea is highlighted in a 2019 article from Nature Medicine, which discusses how compatibility with professional ethics influences AI adoption among healthcare workers. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
This means researchers need to look closely at how healthcare professionals interact with AI tools, how well these systems fit into existing workflows, and the overall usability. Understanding these factors helps ensure AI is designed and implemented in ways that professionals actually want to use. |
The 2019 Nature Medicine article highlights the importance of user-centered research for successful AI adoption in healthcare. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease causes the degeneration of dopamine-producing neurons in the brain. Human embryonic stem cells can develop into these neurons, potentially restoring the dopamine levels and improving motor symptoms in patients. |
Barker, R.A., et al. (2017). “Human embryonic stem cells and their potential for treating Parkinson’s disease.” Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
Monkeys are often chosen for these studies because their brain structure and function are closer to humans, making them valuable for assessing how well stem cell treatments might work and ensuring safety before moving to human trials. |
Barker, R.A., et al. (2017). Preclinical testing of stem cell therapies for Parkinson’s disease. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The preclinical safety study in rats lasted 9 months, which is a significant duration for evaluating potential long-term effects and risks associated with the stem cell therapy. Conducting a study over this period allows researchers to carefully observe the treated animals for any adverse reactions, tumor formation, or other safety concerns that might arise after transplantation. This thorough monitoring is crucial before advancing to human clinical trials to ensure the therapy is both effective and safe over time. |
Barker, R.A., et al. (2017). Preclinical safety assessment of stem cell therapies for Parkinson’s disease. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
This combined phase focuses first on evaluating the safety (Phase I) and then the initial effectiveness (Phase IIa) of the stem cell therapy in patients with Parkinson’s disease. It’s an important step before larger-scale trials. |
Barker, R.A., et al. (2017). Clinical development of stem cell therapies for Parkinson’s disease. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product is manufactured under GMP-compliant conditions, which stands for Good Manufacturing Practice. This means the entire process follows strict regulatory guidelines to ensure the product’s quality, safety, and consistency. Manufacturing under GMP conditions is essential because stem cell therapies involve living cells that must be carefully controlled to avoid contamination, variability, or harmful effects. This rigorous process also includes detailed documentation and regular inspections to meet the high standards required before any clinical use in patients. Without GMP compliance, the product wouldn’t be allowed in clinical trials or approved for treatment. |
Barker, R.A., et al. (2017). Manufacturing standards for stem cell therapies in Parkinson’s disease. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
According to the article, the safety of the STEM-PD product in rats was confirmed by the absence of harmful side effects, including no tumor formation or unexpected biological responses. This result was critical in demonstrating that the stem cell-derived therapy could be safely implanted into the brain without causing long-term damage or uncontrolled cell growth—two major concerns in regenerative medicine. The 9-month preclinical study specifically monitored for such risks to ensure the product was safe before moving forward with human trials. |
Barker, R.A., et al. (2017). Preclinical safety assessment of stem cell therapies for Parkinson’s disease. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
In the efficacy study of STEM-PD, a key finding was that the transplanted human embryonic stem cell-derived dopamine neurons successfully reversed motor deficits in rat models of Parkinson’s disease. This is a significant outcome, as motor symptoms—such as tremors, rigidity, and slow movement—are hallmark features of the disease. The recovery of motor function in rats suggests that the transplanted cells not only survived but also integrated functionally into the brain and produced dopamine, the neurotransmitter lacking in Parkinson’s patients. This finding supported the progression to human clinical trials. |
Barker, R.A., et al. (2017). Functional recovery in Parkinsonian rats following stem cell therapy. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
GIRK2 and ALDH1A1 |
|
In the study, GIRK2 and ALDH1A1 were used as specific markers to assess the purity of the STEM-PD batch, particularly to confirm the identity and maturity of the dopamine neurons derived from human embryonic stem cells. These markers are strongly associated with midbrain A9-type dopaminergic neurons, which are the subtype most affected in Parkinson’s disease. Ensuring the transplanted cells express these markers is essential for both safety and effectiveness, as it confirms the cells are the right type for replacing the lost neurons in patients. |
Barker, R.A., et al. (2017). Characterization of dopaminergic neuron populations in stem cell therapy for Parkinson’s. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
In the manufacturing process of STEM-PD, growth factors like FGF8b (Fibroblast Growth Factor 8b) and SHH (Sonic Hedgehog) play a critical role in guiding the differentiation of human embryonic stem cells into specific types of neural cells—particularly midbrain dopaminergic neurons. These growth factors mimic key developmental signals from the embryonic brain, helping to “pattern” the stem cells so they become the exact neuron subtype (A9 dopaminergic neurons) that is lost in Parkinson’s disease. This precision in cell fate specification is vital to ensure the safety, functionality, and therapeutic effectiveness of the final cell product. |
Barker, R.A., et al. (2017). Developmental signaling in stem cell-derived therapies for Parkinson’s disease. Nature Medicine, 23(11), 1400–1410.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
In the preclinical trials of STEM-PD, the recovery of motor function in rats was the key outcome used to measure efficacy. Parkinson’s disease primarily affects movement due to the loss of dopamine-producing neurons in the brain. The study transplanted human stem cell-derived dopamine neurons into rats with Parkinson-like symptoms. Researchers then evaluated improvements in tasks related to movement—such as walking and coordination—to determine whether the therapy was working. The observed recovery of motor abilities indicated that the transplanted cells were functional and capable of restoring lost neurological activity. |
Barker, R.A., et al. (2017). Functional efficacy of stem cell-derived dopamine neurons in Parkinsonian rats. Nature Medicine, 23(11), 1400–1410. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|